Supporting the role of TNF-α in the pathogenesis of diabetes, cohorts receiving anti-TNF-α therapy, particularly infliximab, have shown significantly lower mean blood glucose levels and reduced insulin resistance. Here, TNF is linked to Insulin resistance.